Rapamycin, a drug that targets a genetic signaling pathway linked to aging and immune function, has been studied in animal models for its potential use as an anti-aging therapeutic. A team from Novartis administered an experimental medication, a version of the drug rapamycin, to a group of older men and women. The subjects displayed an improved immune response to a flu vaccine of 20%. The study authors submit that: “These results raise the possibility that mTOR inhibition may have beneficial effects on immunosenescence in the elderly.”
:
